ImmuPharma PLC | Income Statement
Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
184.80
76.40
164.80
150.50
81.30
Cost of Goods Sold (COGS) incl. D&A
55.90
-
-
-
-
-
Gross Income
55.90
-
-
-
-
-
SG&A Expense
4,172.20
3,510.10
4,517.80
6,632.60
7,246.30
8,028.40
EBIT
4,228.10
3,424.90
4,563.10
6,589.20
7,234.00
8,080.20
Unusual Expense
-
-
-
296.10
-
-
Non Operating Income/Expense
266.10
26.20
4.30
21.20
239.70
117.30
Interest Expense
0.10
14.20
1.20
1.90
3.90
4.80
Pretax Income
4,433.90
3,340.20
4,548.50
6,314.40
6,997.40
7,955.20
Income Tax
744.50
468.70
651.00
990.40
774.20
748.60
Consolidated Net Income
3,689.30
2,871.50
3,897.50
5,324.00
6,223.20
7,206.50
Net Income
3,689.30
2,871.50
3,897.50
5,324.00
6,223.20
7,206.50
Net Income After Extraordinaries
3,689.30
2,871.50
3,897.50
5,324.00
6,223.20
7,206.50
Net Income Available to Common
3,689.30
2,871.50
3,897.50
5,324.00
6,223.20
7,206.50
EPS (Basic)
0.05
0.03
0.04
0.05
0.05
0.05
Basic Shares Outstanding
81,663.10
83,602.60
88,622.50
117,340.50
130,902.90
138,839.60
EPS (Diluted)
0.05
0.03
0.04
0.05
0.05
0.05
Diluted Shares Outstanding
81,663.10
83,602.60
88,622.50
117,340.50
130,902.90
138,839.60
EBITDA
4,172.20
3,325.30
4,441.40
6,467.80
7,095.80
7,947.10
Non-Operating Interest Income
60.40
72.80
11.50
1.70
0.80
12.50
About ImmuPharma
View Profile
